Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis-Reference-Cited by-同舟云学术

Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Published:2017-01 Issue:1 Volume:3 Page:e000396
ISSN:2056-5933
Container-title:RMD Open
language:en
Short-container-title:RMD Open

Author:

Sepriano Alexandre^ORCID,Regel Andrea,van der Heijde Désirée,Braun Jürgen,Baraliakos Xenofon,Landewé Robert,Van den Bosch Filip,Falzon Louise,Ramiro Sofia

Publisher

BMJ

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference73 articles.

1. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria;van der Linden;Arthritis Rheum,1984

2. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis;Braun;Ann Rheum Dis,2003

3. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis;Braun;Ann Rheum Dis,2006

4. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis;van der Heijde;Ann Rheum Dis,2011

5. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection;Rudwaleit;Ann Rheum Dis,2009

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative real-world retention rate and safety of Biosimilar IBI303 versus Humira in Ankylosing Spondylitis;2024-07-29

2. The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study;BMC Rheumatology;2024-01-25

3. Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network;Scientific Reports;2024-01-16

4. Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry;Current Medical Research and Opinion;2023-12-15

5. Beyond the horizon: Innovations and future directions in axial-spondyloarthritis;Archives of Rheumatology;2023-11-22